Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of ...

Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ...

Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...

Logistic regression analyses were performed to evaluate the predictive capacity of clinical and microbial factors for treatment outcomes. Conclusions: The composition and functional characteristics of ...

Scientists found that aggressive lung cancer cells create their own electrical network, helping them spread. This unique ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

A new large-scale study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators provides the strongest ...

The WOLVERINE study analyzed five trials and found metastasis-directed therapy -- primarily radiation -- may delay castration ...

Bristol Myers (BMY)’ treatment of small cell lung cancer, atigotatug plus nivolumab fixed dose combination, received FDA ...

In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.

Radiation therapy for prostate cancer can cause short-term side effects such as diarrhea, urine changes, and more. Long-term side effects such as urinary and bowel problems may also occur.